Tong Ren Tang Technologies Co. Ltd. (TGRNF)
USD 0.69
(0.0%)
USD 0.69
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 590.18 Million CNY | 1.25% |
| 2022 | 582.88 Million CNY | 14.91% |
| 2021 | 507.24 Million CNY | 8.49% |
| 2020 | 467.55 Million CNY | 11.95% |
| 2019 | 417.65 Million CNY | -38.38% |
| 2018 | 677.81 Million CNY | 1.67% |
| 2017 | 666.66 Million CNY | 11.92% |
| 2016 | 595.65 Million CNY | 10.1% |
| 2015 | 541.03 Million CNY | 17.06% |
| 2014 | 462.18 Million CNY | 18.48% |
| 2013 | 390.09 Million CNY | 18.15% |
| 2012 | 330.18 Million CNY | 29.64% |
| 2011 | 254.68 Million CNY | 28.64% |
| 2010 | 197.97 Million CNY | 12.25% |
| 2009 | 176.36 Million CNY | 9.87% |
| 2008 | 160.52 Million CNY | 4.3% |
| 2007 | 153.91 Million CNY | 3.77% |
| 2006 | 148.32 Million CNY | -35.84% |
| 2005 | 231.18 Million CNY | 12.44% |
| 2004 | 205.6 Million CNY | 19.7% |
| 2003 | 171.76 Million CNY | 18.55% |
| 2002 | 144.88 Million CNY | 45.0% |
| 2001 | 99.91 Million CNY | 83.74% |
| 2000 | 54.37 Million CNY | 42.14% |
| 1999 | 38.25 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 59.48 Million USD | 0.0% |
| 2023 FY | 590.18 Million CNY | 1.25% |
| 2023 Q2 | 53.11 Million USD | 0.0% |
| 2023 Q4 | 30.71 Million USD | 0.0% |
| 2022 Q4 | 38 Million USD | 0.0% |
| 2022 Q2 | 48.97 Million USD | 0.0% |
| 2022 FY | 582.88 Million CNY | 14.91% |
| 2021 Q2 | 48.74 Million USD | 0.0% |
| 2021 FY | 507.24 Million CNY | 8.49% |
| 2021 Q4 | 29.76 Million USD | 0.0% |
| 2020 FY | 467.55 Million CNY | 11.95% |
| 2020 Q4 | 28.91 Million USD | 0.0% |
| 2020 Q2 | 38.67 Million USD | 0.0% |
| 2019 Q2 | 56.61 Million USD | 0.0% |
| 2019 FY | 417.65 Million CNY | -38.38% |
| 2019 Q4 | 5 Million USD | 0.0% |
| 2018 FY | 677.81 Million CNY | 1.67% |
| 2017 FY | 666.66 Million CNY | 11.92% |
| 2016 FY | 595.65 Million CNY | 10.1% |
| 2015 FY | 541.03 Million CNY | 17.06% |
| 2014 FY | 462.18 Million CNY | 18.48% |
| 2013 FY | 390.09 Million CNY | 18.15% |
| 2012 FY | 330.18 Million CNY | 29.64% |
| 2011 FY | 254.68 Million CNY | 28.64% |
| 2010 FY | 197.97 Million CNY | 12.25% |
| 2009 FY | 176.36 Million CNY | 9.87% |
| 2008 FY | 160.52 Million CNY | 4.3% |
| 2007 FY | 153.91 Million CNY | 3.77% |
| 2006 FY | 148.32 Million CNY | -35.84% |
| 2005 FY | 231.18 Million CNY | 12.44% |
| 2004 FY | 205.6 Million CNY | 19.7% |
| 2003 FY | 171.76 Million CNY | 18.55% |
| 2002 FY | 144.88 Million CNY | 45.0% |
| 2001 FY | 99.91 Million CNY | 83.74% |
| 2000 FY | 54.37 Million CNY | 42.14% |
| 1999 FY | 38.25 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AstraZeneca PLC | 5.95 Billion USD | 90.089% |
| Bristol-Myers Squibb Company PFD CONV 2 | 8.02 Billion USD | 92.646% |
| CSPC Pharmaceutical Group Limited | 830.91 Million USD | 28.971% |
| Clarus Therapeutics Holdings, Inc. | -56.51 Million USD | 1144.359% |
| Novartis AG | 14.85 Billion USD | 96.026% |
| PT Kalbe Farma Tbk. | 179.7 Million USD | -228.419% |